ClinicalTrials.gg
TerminatedNCT03206047Updated Oct 20, 2026Results posted

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase 1/2 interventional study of Atezolizumab and DEC-205/NY-ESO-1 Fusion Protein CDX-1401 in Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma and Platinum-Resistant Primary Peritoneal Carcinoma, sponsored by National Cancer Institute (NCI). Terminated at 17 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by National Cancer Institute (NCI) · Phase 1/2, Interventional, and Treatment

How we know · 9 judgments

Why this study was terminated
The study was terminated due to a shortage of the drug supply.
Updated Oct 20, 2026Now TerminatedResults posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 82 studies in Fallopian Tube Neoplasms by National Cancer Institute (NCI) — 1 open to participants now, 20 under way, 5 of them phase 3. Fallopian Tube Neoplasms · National Cancer Institute (NCI).

Enrollment
70th of 73
9 · median 50
Started
2017
with 4 others
Phase 1/2
5 of 82
none open now
Registered
74th of 82
by date

Among the 82 studies in Fallopian Tube Neoplasms by National Cancer Institute (NCI), this one is the 70th largest by enrollment of the 73 interventional ones that give a count, is one of 5 that started in 2017, is one of 5 in phase 1/2, and was the 74th registered.

Fallopian Tube Neoplasms

835 studies on the registry are indexed under Fallopian Tube Neoplasms; 128 are open to participants now.

Browse Fallopian Tube Neoplasms studies →

Open to participants now

1 of the 82 studies in Fallopian Tube Neoplasms by National Cancer Institute (NCI) is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 104 Fallopian Tube Neoplasms studies recruiting now, 85 (82%) set no upper age limit and 10 (10%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Fallopian Tube Neoplasms by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This randomized phase I/IIb trial studies side effects and best dose of atezolizumab when given together with guadecitabine and CDX-1401 vaccine and to see how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CDX-1401 vaccine may enhance the expression of the genes encoding tumor antigens on the surface of tumor cells and enhance the activity of tumor-killing T cells against those tumor cells. Vaccines made from monoclonal antibodies combined with tumor cells may help the body build an effective immune response to kill tumor cells. Giving atezolizumab, guadecitabine, and CDX-1401 vaccine may work better than CDX-1401 alone in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine the safety of fixed doses of atezolizumab (MPDL3280A) in combination with guadecitabine (SGI-110). (Phase I) II. To evaluate toxicity of the combination as defined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. (Phase I) III. To study if SGI-110 improves the benefit of atezolizumab and then if the further addition of the DEC-205/NY-ESO-1 fusion protein CDX-1401 (CDX-1401)/poly ICLC adds further clinical benefit by analyzing progression free survival (PFS), using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. (Phase IIb)

SECONDARY OBJECTIVES:

I. To observe and record anti-tumor activity. (Phase I) II. To determine overall survival (OS), objective response rate (complete and partial responses), clinical benefit rate (response + stable disease), CA-125 reduction (percentage of patients with CA-125 reduction by >= 50%), and duration of response. (Phase IIb) III. To assess the impact of the combination of atezolizumab, SGI-110, and CDX-1401 on anti-tumor immune responses. (Phase IIb) IV. To assess the impact of SGI-110 on NY-ESO-1 expression in tumor tissue. (Phase IIb) V. To assess toxicities associated with the combination cohorts (2 and 3), as there is little human experience with these combinations. (Phase IIb)

EXPLORATORY/TRANSLATIONAL OBJECTIVES:

I. To determine the effectiveness of SGI-110 on enhancing vaccine efficacy by assessing NY ESO 1 specific cellular and humoral immunity.

Ia. Peripheral blood NY ESO 1 specific CD8+ and CD4+ T cells. Ib. Peripheral blood NY ESO 1 specific antibodies. Ic. Peripheral blood unrelated CTA specific antibodies (antigen spreading). Id. Peripheral blood frequency of CD4+CD25+FOXP3+ regulatory T cells. Ie. Examine potential differential effect of NY-ESO-1 expression on PFS. II. To assess the impact on PDL1 expression in tumor tissue. III. Evaluation of therapeutic efficacy on immune cell phenotype. IV. Deoxyribonucleic acid (DNA) methylation and DNA methylome: in pre- and on-treatment peripheral blood, serum (circulating DNA), and tumor biopsies.

V. Pre-and on-treatment density and location of tumor infiltrating CD3+ and CD8+ T cells.

VI. Evaluate the pre- and post-treatment mutational and neo-antigen load and therapeutic efficacy.

VII. Pre- and post-treatment T cell receptor (TCR) repertoire to study the effect of TCR V beta diversity due to combination of PDL1 blockade, epigenetic modification, and vaccination on therapeutic efficacy.

VIII. Gut microbiota at baseline and one on-treatment sample at C4D1 (cycle 4, day 1) or at progression, whichever is earlier to evaluate the role of microbiota on the therapeutic efficacy of the proposed combination therapy.

OUTLINE: This is a phase I, dose-escalation study of guadecitabine followed by a phase IIb study. Patients are randomized to 1 of 3 cohorts.

COHORT I: Patients receive atezolizumab intravenously (IV) over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.

COHORT II: Patients receive guadecitabine subcutaneously (SC) on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on days 8 and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.

COHORT III: Patients receive guadecitabine and atezolizumab as in Cohort II. Patients also receive CDX-1401 vaccine IV on day 15 and poly ICLC SC on days 15-16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and then every 2 months for up to 1 year.

03

Conditions studied

  • Platinum-Resistant Fallopian Tube Carcinoma
  • Platinum-Resistant Ovarian Carcinoma
  • Platinum-Resistant Primary Peritoneal Carcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Primary Peritoneal Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with platinum-resistant disease (defined as having within 6 months of last platinum-containing regimen because we would like to include both primary and secondary resistance); patients are allowed to have had more than 2 prior cytotoxic treatment regimens; all patients should have received standard of care agents, which confer clinical benefit
  • Presence of biopsiable disease and patient able to undergo pre-treatment and on-treatment
  • Tissue available from primary and/or recurrent disease to evaluate tumor expression of NY-ESO-1 or PDL1 by immunohistochemistry (IHC) and/or reverse transcriptase-polymerase chain reaction (RT-PCR), and for measurement of DNA methylation
  • No requirement for tumor expression of NY-ESO-1
  • > 6 months as assessed by study physician
  • Because no dosing or adverse event data are currently available on the use of atezolizumab in combination with SGI-110 and CDX-1401 in patients \< 18 years of age, children are excluded from this study, but may be eligible for future pediatric trials
  • (ECOG) performance status =\< 2
  • Have been informed of other treatment options
  • Have outside of biopsy site present per immune related (ir) criteria; (Rationale: Biopsy may also induce an inflammatory response and bias outcome measurements)
  • Patients may have received previous NY ESO 1 vaccine therapy; patients who received bevacizumab or other experimental therapies are eligible for enrollment provided they have discontinued therapy (at least 4 weeks) prior to randomization and recovered from toxicities to less than grade 2
  • Leukocytes >= 2,500/mcL
  • >= 1,500/mcL
  • >= 100,000/mcL
  • >= 10 g/dL
  • Total =\< 1.5 x institutional (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =\< 3 x ULN may be enrolled)
  • (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =\< 1.5 x ULN (AST and/or ALT =\< 3 x ULN for patients with liver involvement)
  • Alkaline phosphatase =\< 2 x ULN (=\< 5 x ULN for patients with documented liver involvement or bone )
  • >= 30 mL/min/1.73 m\^2 by Cockcroft-Gault
  • (INR) and activated partial thromboplastin time (aPTT) =\< 1.5 x ULN
  • Administration of the drugs used in this study may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; women of must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of study agent; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately
  • Participant or legal representative must understand the nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written form prior to receiving any study related procedure

Exclusion criteria

Exclusion Criteria:

  • Patients with prior bone marrow transplantation or prior solid organ transplantation
  • Patients who have had chemotherapy or radiotherapy including complementary and alternative medicine treatments (CAMs) within 4 weeks prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier
  • Prior treatment with , or anti-PD-L1 therapeutic antibody or pathway-targeting agents

    • Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:

      • Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose
      • No history of severe immune-related adverse effects from anti-CTLA-4 ( grade 3 and 4)
  • Treatment with any other agent within 4 weeks prior to cycle 1, day 1
  • Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to cycle 1, day 1
  • Treatment with systemic medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1

    • Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled
    • The use of inhaled and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
  • Patients taking bisphosphonate therapy for symptomatic hypercalcemia; use of bisphosphonate therapy for other reasons (e.g., bone or osteoporosis) is allowed
  • Concomitant systemic treatment with chronic use of anti-histamine or non-steroidal anti-inflammatory drugs and other inhibitory agents and patients on oral anticoagulant (e.g. warfarin); exception: patients on therapeutic anticoagulation therapy such as low-molecular-weight heparin or warfarin at a stable dose level are allowed on study
  • Patients with known primary central nervous system (CNS) or symptomatic are excluded
  • Known to Chinese hamster ovary cell products or other recombinant human antibodies
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  • History of allergic reactions attributed to compounds of similar chemical or biological composition to other agents used in this study
  • Subjects who have received prior therapy with hypomethylating agents (5-azacytidine, decitabine, SGI-110)
  • Mental impairment that may compromise the ability to give and comply with the requirements of the study
  • Lack of ability of a patient for immunological and clinical follow-up assessment
  • Evidence of current drug or alcohol abuse or psychiatric impairment, which in the investigator's opinion will prevent completion of protocol therapy or follow-up
  • Due to unknown effects on the developing fetus or newborn, pregnant or nursing female patients are excluded from this study
  • Unwilling or unable to follow protocol requirements
  • Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug. (i.e., any significant medical illness or abnormal laboratory finding that would increase the patient's risk by participating in this study)
  • Known liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease

    • Patients with past or resolved infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible
    • Patients positive for virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)
  • History or risk of disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis

    • Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible
    • Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible
    • Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:

      • Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations
      • Rash must cover less than 10% of body surface area (BSA)
      • Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
      • No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
  • History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted
  • Patients with active tuberculosis (TB) are excluded
  • Severe infections within 4 weeks prior to cycle 1, day 1, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
  • Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
  • Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or ) are eligible
  • Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study
  • Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab

    • Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study and until 5 months after the last dose of atezolizumab
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients positive for (HIV) are NOT excluded from this study, but HIV-positive patients must have:

    • A stable regimen of highly active anti-retroviral therapy (HAART)
    • No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections
    • A above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests
  • Patients requiring treatment with a RANKL inhibitor (e.g. denosumab) who cannot discontinue it before treatment with atezolizumab
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Cohort I (atezolizumab)

    Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.

    Drug: Atezolizumab · Other: Laboratory Biomarker Analysis

  • Experimental
    Cohort II (guadecitabine, atezolizumab)

    Patients receive guadecitabine SC on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on days 8 and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.

    Drug: Atezolizumab · Drug: Guadecitabine · Other: Laboratory Biomarker Analysis

  • Experimental
    Cohort III (guadecitabine, atezolizumab, CDX-1401 vaccine)

    Patients receive guadecitabine and atezolizumab as in Cohort II. Patients also receive CDX-1401 vaccine IV on day 15 and poly ICLC SC on days 15-16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

    Drug: Atezolizumab · Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401 · Drug: Guadecitabine · Other: Laboratory Biomarker Analysis · Drug: Poly ICLC

Interventions

  • Given IV

    Also known as: MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq

  • BiologicalDEC-205/NY-ESO-1 Fusion Protein CDX-1401

    Drug page: Rasdegafusp alfaStudies of Rasdegafusp alfaRasdegafusp alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given SC

    Also known as: CDX-1401

  • Given SC

    Also known as: DNMT inhibitor SGI-110, S110, SGI 110, SGI-110, SGI110

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • Given SC

    Also known as: Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AE) (Phase I)

    The number of patients that had a maximum adverse event \>= grade 4 ( Common Terminology Criteria for Adverse Events version 5.0)

    Time frame: Up to 30 days after last dose

  2. Progression Free Survival (PFS) (Phase IIb)

    The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Progression free survival (PFS) (Phase IIb) is not evaluable.

    Time frame: Till primary study completion date, approximately 3 years

Secondary outcomes

  1. Anti-tumor Activity (Phase I) II

    The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. Anti-tumor activity was not collected.

    Time frame: Up to 1 year

  2. Overall Survival (OS) (Phase IIb)

    The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Overall survival (OS) (Phase IIb) is not evaluable.

    Time frame: Till primary study completion date, approximately 3 years

  3. Objective Response Rate (Phase IIb)

    The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. TheObjective response rate (Phase IIb) is not evaluable.

    Time frame: After 30 days after the last dose of study drug

  4. Clinical Benefit Rate (Phase IIb)

    The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Clinical benefit rate (Phase IIb) is not evaluable.

    Time frame: After 30 days after the last dose of study drug

  5. CA-125 Reduction (Phase IIb)

    The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The CA-125 reduction (Phase IIb) is not evaluable.

    Time frame: CA-125 were followed up from the start date of intervention till 39 months.

  6. Duration of Response (Phase IIb)

    The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Duration of response (Phase IIb) is not evaluable.

    Time frame: After 30 days after the last dose of study drug

  7. Anti-tumor Immune Responses

    The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Anti-tumor immune responses (Phase IIb) is not evaluable.

    Time frame: Anti-tumor immune responses were followed up from the start date of intervention till 39 months.

  8. Epigenetic Modification of Immune Gene Signatures, NY-ESO-1, Other CTAs, and PDL 1 in the Tumor Microenvironment

    The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Epigenetic modification of immune gene signatures, NY-ESO-1, other CTAs, and PDL 1 in the tumor microenvironment (Phase IIb) is not evaluable.

    Time frame: Epigenetic modification of immune gene signatures, NY-ESO-1, other CTAs, and PDL 1 in the tumor microenvironment were followed up from the start date of intervention till 39 months.

  9. Incidence of Adverse Events With the Combination Cohorts (2 and 3) (Phase IIb)

    The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Incidence of adverse events with the combination cohorts (2 and 3) (Phase IIb) is not evaluable.

    Time frame: Incidence of adverse events with the combination cohorts (2 and 3) (Phase IIb) were followed up from the start date of intervention till 39 months.

07

Results

Posted Oct 20, 2026

Participant flow

The study was terminated in 2020 early due to the cellular product being discontinued. Hence only 9 (instead of 12 as proposed in the protocol) patients were accrued by the termination time.

Participant flow — Overall Study
MilestoneCohort II (Guadecitabine, Atezolizumab)Cohort I (Atezolizumab)Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine)Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose Guadecitabine
Started3006
Completed3006
Not completed0000

Outcome measures

PrimaryIncidence of Adverse Events (AE) (Phase I)

The number of patients that had a maximum adverse event \>= grade 4 ( Common Terminology Criteria for Adverse Events version 5.0)

Time frame:
Up to 30 days after last dose
Reported as:
Count of participants · Participants
Incidence of Adverse Events (AE) (Phase I)
ParticipantsCohort I (Atezolizumab)Cohort II (Guadecitabine, Atezolizumab)Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine)Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose Guadecitabine
Incidence of Adverse Events (AE) (Phase I)0006
PrimaryProgression Free Survival (PFS) (Phase IIb)

The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Progression free survival (PFS) (Phase IIb) is not evaluable.

Time frame:
Till primary study completion date, approximately 3 years

No measurements were reported for this outcome.

SecondaryAnti-tumor Activity (Phase I) II

The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. Anti-tumor activity was not collected.

Time frame:
Up to 1 year

No measurements were reported for this outcome.

SecondaryOverall Survival (OS) (Phase IIb)

The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Overall survival (OS) (Phase IIb) is not evaluable.

Time frame:
Till primary study completion date, approximately 3 years

No measurements were reported for this outcome.

SecondaryObjective Response Rate (Phase IIb)

The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. TheObjective response rate (Phase IIb) is not evaluable.

Time frame:
After 30 days after the last dose of study drug

No measurements were reported for this outcome.

SecondaryClinical Benefit Rate (Phase IIb)

The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Clinical benefit rate (Phase IIb) is not evaluable.

Time frame:
After 30 days after the last dose of study drug

No measurements were reported for this outcome.

SecondaryCA-125 Reduction (Phase IIb)

The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The CA-125 reduction (Phase IIb) is not evaluable.

Time frame:
CA-125 were followed up from the start date of intervention till 39 months.

No measurements were reported for this outcome.

SecondaryDuration of Response (Phase IIb)

The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Duration of response (Phase IIb) is not evaluable.

Time frame:
After 30 days after the last dose of study drug

No measurements were reported for this outcome.

SecondaryAnti-tumor Immune Responses

The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Anti-tumor immune responses (Phase IIb) is not evaluable.

Time frame:
Anti-tumor immune responses were followed up from the start date of intervention till 39 months.

No measurements were reported for this outcome.

SecondaryEpigenetic Modification of Immune Gene Signatures, NY-ESO-1, Other CTAs, and PDL 1 in the Tumor Microenvironment

The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Epigenetic modification of immune gene signatures, NY-ESO-1, other CTAs, and PDL 1 in the tumor microenvironment (Phase IIb) is not evaluable.

Time frame:
Epigenetic modification of immune gene signatures, NY-ESO-1, other CTAs, and PDL 1 in the tumor microenvironment were followed up from the start date of intervention till 39 months.

No measurements were reported for this outcome.

SecondaryIncidence of Adverse Events With the Combination Cohorts (2 and 3) (Phase IIb)

The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Incidence of adverse events with the combination cohorts (2 and 3) (Phase IIb) is not evaluable.

Time frame:
Incidence of adverse events with the combination cohorts (2 and 3) (Phase IIb) were followed up from the start date of intervention till 39 months.

No measurements were reported for this outcome.

Adverse events

Collected over Routine AE's will be reported from the start date of intervention, at all visits except for week six till last follow up up to 36 months after treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort I (Atezolizumab)———
Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine)———
Cohort II (Guadecitabine, Atezolizumab)3/3 (100%)3/3 (100%)3/3 (100%)
Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose Guadecitabine4/6 (66.7%)5/6 (83.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventCohort I (Atezolizumab)Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine)Cohort II (Guadecitabine, Atezolizumab)Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose Guadecitabine
FeverGeneral disorders——2/30/6
Abdominal distensionGastrointestinal disorders——1/30/6
Abdominal painGastrointestinal disorders——1/30/6
BloatingGastrointestinal disorders——1/30/6
Small intestinal obstructionGastrointestinal disorders——1/30/6
small bowel obstructionGastrointestinal disorders——1/30/6
disease progressionGeneral disorders——0/32/6
Tooth infectionInfections and infestations——1/30/6
hydronephrosisRenal and urinary disorders——1/30/6
AnemiaBlood and lymphatic system disorders——0/31/6
Most frequent other events
Showing 10 of 76
Most frequent other events
EventCohort I (Atezolizumab)Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine)Cohort II (Guadecitabine, Atezolizumab)Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose Guadecitabine
Alkaline phosphatase increasedInvestigations——3/31/6
AnemiaBlood and lymphatic system disorders——2/32/6
FatigueGeneral disorders——2/33/6
HyponatremiaMetabolism and nutrition disorders——1/34/6
ProteinuriaRenal and urinary disorders——2/30/6
ConstipationGastrointestinal disorders——1/33/6
Aspartate aminotransferase increasedInvestigations——1/33/6
Neutrophil count decreasedInvestigations——1/33/6
EosinophiliaBlood and lymphatic system disorders——1/30/6
Increased LDHBlood and lymphatic system disorders——1/30/6

Baseline characteristics

The study was terminated in 2020 early due to the cellular product being discontinued.

Age, Categorical
Age, Categorical(Participants)Cohort I (Atezolizumab)Cohort II (Guadecitabine, Atezolizumab)Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine)Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose GuadecitabineTotal
<=18 years00000
Between 18 and 65 years03025
>=65 years00044
Age, Continuous
Age, Continuous(years)Cohort I (Atezolizumab)Cohort II (Guadecitabine, Atezolizumab)Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine)Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose GuadecitabineTotal
Median—47 (45 to 57)—69.5 (54 to 76)57 (45 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort I (Atezolizumab)Cohort II (Guadecitabine, Atezolizumab)Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine)Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose GuadecitabineTotal
Female03069
Male00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort I (Atezolizumab)Cohort II (Guadecitabine, Atezolizumab)Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine)Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose GuadecitabineTotal
American Indian or Alaska Native00000
Asian01001
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White02068
More than one race00000
Unknown or Not Reported00000
08

Study locations

17 sites
  • Banner University Medical Center - Tucson
    Tucson, Arizona 85719, United States
  • University of Arizona Cancer Center-North Campus
    Tucson, Arizona 85719, United States
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
  • University of California Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • University of Chicago Comprehensive Cancer Center
    Chicago, Illinois 60637, United States
  • UC Comprehensive Cancer Center at Silver Cross
    New Lenox, Illinois 60451, United States
  • University of Chicago Medicine-Orland Park
    Orland Park, Illinois 60462, United States
  • University of Kansas Clinical Research Center
    Fairway, Kansas 66205, United States
  • Nebraska Medicine-Village Pointe
    Omaha, Nebraska 68118, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone
    New York, New York 10016, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • University of Pittsburgh Cancer Institute (UPCI)
    Pittsburgh, Pennsylvania 15232, United States
  • Huntsman Cancer Institute/University of Utah
    Salt Lake City, Utah 84112, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Nov 2020, 36 months.

Results were first posted in Oct 2026, 5 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2017
First posted
Jul 2, 2017
StartActual
Nov 8, 2017
Primary completionActual
Nov 10, 2020
CompletionActual
Nov 10, 2020
Results first posted
Oct 20, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated The study was terminated due to a shortage of the drug supply.
changed Oct 20, 2026
Results
Results posted
posted Oct 20, 2026
Enrollment
12→9
Oct 20, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedIncidence of adverse eventsAdverse Events (AE) (Phase I)Time frame: Up to 30 days after last dose
  • EditedProgression free survivalFree Survival (PFS) (Phase IIb)Time frame: Up to 1 year → Till primary study completion date, approximately 3 years
Oct 20, 2026
Secondary outcomes
9 edited, 7 removed
What changed in the outcomes
  • EditedAnti-tumor activityActivity (Phase I) IITime frame: Up to 1 year
  • EditedOverall survivalSurvival (OS) (Phase IIb)Time frame: Up to 1 year → Till primary study completion date, approximately 3 years
  • EditedObjective response rateResponse Rate (Phase IIb)Time frame: Up to 1 year → After 30 days after the last dose of study drug
  • EditedClinical benefit rateBenefit Rate (Phase IIb)Time frame: Up to 1 year → After 30 days after the last dose of study drug
  • EditedCA-125 reductionReduction (Phase IIb)Time frame: Up to 1 year → CA-125 were followed up from the start date of intervention till 39 months.
  • EditedDuration of responseResponse (Phase IIb)Time frame: Up to 1 year → After 30 days after the last dose of study drug
  • EditedAnti-tumor immune responses (Phase IIb)Immune ResponsesTime frame: Up to 1 year → Anti-tumor immune responses were followed up from the start date of intervention till 39 months.
  • EditedEpigenetic modificationModification of immune gene signaturesImmune Gene Signatures, NY-ESO-1, otherOther CTAs, and PDL1PDL 1 in the tumor microenvironment (Phase IIb)Tumor MicroenvironmentTime frame: Up to 1 year → Epigenetic modification of immune gene signatures, NY-ESO-1, other CTAs, and PDL 1 in the tumor microenvironment were followed up from the start date of intervention till 39 months.
  • EditedIncidence of adverse events withAdverse Events With the combination cohortsCombination Cohorts (2 and 3) (Phase IIb)Time frame: Up to 30 days after last dose → Incidence of adverse events with the combination cohorts (2 and 3) (Phase IIb) were followed up from the start date of intervention till 39 months.
  • Removedother outcomeNY-ESO-1-specific immune responsesTime frame: Up to 1 year
  • Removedother outcomePDL1 expression in tumor tissueTime frame: Up to 1 year
  • Removedother outcomeAIM gene signaturesTime frame: Up to 1 year
  • Removedother outcomeImmune cell phenotypeTime frame: Up to 1 year
  • Removedother outcomeNeo-antigen and mutational antigenTime frame: Up to 1 year
  • Removedother outcomeT cell receptor (TCR) repertoireTime frame: Up to 1 year
  • Removedother outcomeMicrobiomeTime frame: Up to 1 year
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Completed→Terminated
    Why stopped The study was terminated due to a shortage of the drug supply.
    Results posted
    Enrollment 12→9
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedIncidence of adverse eventsAdverse Events (AE) (Phase I)Time frame: Up to 30 days after last dose
    • EditedProgression free survivalFree Survival (PFS) (Phase IIb)Time frame: Up to 1 year → Till primary study completion date, approximately 3 years
    Secondary outcomes 9 edited, 7 removed
    What changed in the outcomes
    • EditedAnti-tumor activityActivity (Phase I) IITime frame: Up to 1 year
    • EditedOverall survivalSurvival (OS) (Phase IIb)Time frame: Up to 1 year → Till primary study completion date, approximately 3 years
    • EditedObjective response rateResponse Rate (Phase IIb)Time frame: Up to 1 year → After 30 days after the last dose of study drug
    • EditedClinical benefit rateBenefit Rate (Phase IIb)Time frame: Up to 1 year → After 30 days after the last dose of study drug
    • EditedCA-125 reductionReduction (Phase IIb)Time frame: Up to 1 year → CA-125 were followed up from the start date of intervention till 39 months.
    • EditedDuration of responseResponse (Phase IIb)Time frame: Up to 1 year → After 30 days after the last dose of study drug
    • EditedAnti-tumor immune responses (Phase IIb)Immune ResponsesTime frame: Up to 1 year → Anti-tumor immune responses were followed up from the start date of intervention till 39 months.
    • EditedEpigenetic modificationModification of immune gene signaturesImmune Gene Signatures, NY-ESO-1, otherOther CTAs, and PDL1PDL 1 in the tumor microenvironment (Phase IIb)Tumor MicroenvironmentTime frame: Up to 1 year → Epigenetic modification of immune gene signatures, NY-ESO-1, other CTAs, and PDL 1 in the tumor microenvironment were followed up from the start date of intervention till 39 months.
    • EditedIncidence of adverse events withAdverse Events With the combination cohortsCombination Cohorts (2 and 3) (Phase IIb)Time frame: Up to 30 days after last dose → Incidence of adverse events with the combination cohorts (2 and 3) (Phase IIb) were followed up from the start date of intervention till 39 months.
    • Removedother outcomeNY-ESO-1-specific immune responsesTime frame: Up to 1 year
    • Removedother outcomePDL1 expression in tumor tissueTime frame: Up to 1 year
    • Removedother outcomeAIM gene signaturesTime frame: Up to 1 year
    • Removedother outcomeImmune cell phenotypeTime frame: Up to 1 year
    • Removedother outcomeNeo-antigen and mutational antigenTime frame: Up to 1 year
    • Removedother outcomeT cell receptor (TCR) repertoireTime frame: Up to 1 year
    • Removedother outcomeMicrobiomeTime frame: Up to 1 year
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03206047
Responsible party
Sponsor
First posted
Jul 2, 2017
Start date
Nov 8, 2017
Primary completion
Nov 10, 2020
Completion
Nov 10, 2020
Results posted
Oct 20, 2026
Last update
Oct 20, 2026

Study contacts

Kunle Odunsi
principal investigator · Roswell Park Cancer Institute EDDOP

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion